NeuroSearch A/S (NEUR) was founded in 1989 and is listed on the stock exchange in Copenhagen (NASDAQ Copenhagen A/S). From its inception, the Company has focused its research and development activities on bringing drug candidates to market, primarily in the CNS segment. However, in 2012 the Company had to acknowledge that it was no longer able to attract funding for continuing its R&D activities.
In the autumn of 2012, it was decided to accept an offer to sell all rigths to Huntexil for the treatment of patients with Huntington's disease to Teva Pharmaceuticals. The Comapany's two remaining employees and its Board of Directors are now exploring the possibilities of a controlled disposal of its remaining assets. For a more detailed discussion of the situation, see the Company's Annual Report 2014.
The remaining assets consist of equity investments in the companies NsGene A/S and Atonomics A/S, contingent milestones from agreements with Teva Pharmaceuticals, and an agreement with Saniona A/S, which may also potentially produce royalties. Finally, the Company has a portfolio of drug candidates which have alle been stopped at various stages of therie clinical development.
For a more detailed description of the assets, we also refer to the Annual Report 2014.